Medtronic (NYSE:MDT) Sees Strong Trading Volume – What’s Next?

Medtronic PLC (NYSE:MDT) shares saw unusually-strong trading volume on Tuesday. Approximately 32,780,431 shares changed hands during trading, an increase of 238% from the previous session’s volume of 9,703,300 shares. The stock last traded at $86.5610 and had previously closed at $87.97.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Barclays upgraded Medtronic to Hold from a lower rating, signaling reduced downside concern. The change adds modestly improved Wall Street sentiment, although a Hold rating does not imply strong near-term upside. Medtronic Stock Rating Raised to Hold at Barclays
• Positive Sentiment: Medtronic is one year away from potentially becoming a Dividend King, assuming it continues its annual dividend increases. The company’s long record of shareholder returns and roughly 3% dividend yield may appeal to income-focused investors, particularly while the shares trade below their 52-week high. Medtronic Is Just 1 Year From Dividend King Status
• Positive Sentiment: Medtronic appointed Felicia Kurz as vice president and general manager of cardiac ablation. The leadership move comes as demand for the company’s pulsed-field ablation devices supports growth in electrophysiology, a strategically important market. Medtronic names Felicia Kurz as cardiac ablation VP, GM
• Neutral Sentiment: Medtronic finalized a 4.5939 exchange ratio for its MiniMed split-off. The transaction should further separate the diabetes business and sharpen Medtronic’s focus, but the exchange offer also creates a corporate-action overhang as investors assess the effects on ownership and shares outstanding. Medtronic Announces Final Exchange Ratio
• Neutral Sentiment: Analysts highlighted Medtronic as a high-yield healthcare stock with a dividend yield in the 3.02%-3.86% range across the stocks discussed. The income appeal supports valuation, but the commentary reflects a mixed market view rather than a new earnings catalyst. Wall Street analysts review high-dividend healthcare stocks

Analysts Set New Price Targets

MDT has been the topic of a number of research analyst reports. Bank of America raised their price target on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Robert W. Baird lifted their target price on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a report on Wednesday, September 2nd. Truist Financial reissued a “hold” rating and issued a $99.00 target price (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. BTIG Research upped their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Finally, Barclays raised shares of Medtronic to a “hold” rating in a research note on Wednesday. Eighteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $102.92.

Medtronic Price Performance

The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The company’s 50-day moving average is $90.18 and its 200-day moving average is $84.75. The firm has a market capitalization of $111.98 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 1.98 and a beta of 0.55.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter last year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts expect that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

A number of institutional investors have recently modified their holdings of the stock. Apella Capital LLC increased its position in Medtronic by 65.3% in the third quarter. Apella Capital LLC now owns 5,667 shares of the medical technology company’s stock worth $485,000 after buying an additional 2,239 shares during the period. Everhart Financial Group Inc. grew its position in Medtronic by 9.0% in the third quarter. Everhart Financial Group Inc. now owns 5,719 shares of the medical technology company’s stock worth $493,000 after buying an additional 473 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Medtronic by 11.3% in the 3rd quarter. Valeo Financial Advisors LLC now owns 18,439 shares of the medical technology company’s stock valued at $1,593,000 after acquiring an additional 1,876 shares in the last quarter. Plan A Wealth LLC grew its stake in Medtronic by 2.2% during the 3rd quarter. Plan A Wealth LLC now owns 5,917 shares of the medical technology company’s stock valued at $511,000 after acquiring an additional 129 shares in the last quarter. Finally, City Center Advisors LLC acquired a new position in shares of Medtronic in the third quarter worth $280,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.